HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation

The diversity of human leukocyte antigens (HLAs) enables the presentation of immense repertoires of peptides, including tumor-associated antigens (TAAs). As a surrogate for immunopeptidome diversity, the HLA evolutionary divergence (HED) between individual HLA alleles might directly define the abili...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-07, Vol.12 (7), p.1835
Main Authors: Roerden, Malte, Nelde, Annika, Heitmann, Jonas S., Klein, Reinhild, Rammensee, Hans-Georg, Bethge, Wolfgang A., Walz, Juliane S.
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Antigen (tumor-associated)
Antigen presentation
Antigenic determinants
Cancer
Disease control
Divergence
Hematopoietic stem cells
Immunology
Immunotherapy
Leukemia
Lymphocytes
Myeloid leukemia
Patients
Peptides
Stem cell transplantation
Stem cells
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diversity of human leukocyte antigens (HLAs) enables the presentation of immense repertoires of peptides, including tumor-associated antigens (TAAs). As a surrogate for immunopeptidome diversity, the HLA evolutionary divergence (HED) between individual HLA alleles might directly define the ability to present TAAs, a prerequisite for graft-versus-leukemia effects. We therefore analyzed the impact of HED on survival within a cohort of 171 acute myeloid leukemia (AML) patients after matched donor allogeneic hematopoietic stem cell transplantation (HSCT). Low HED (
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12071835